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Abstract
The neuronal damage characteristic of HIV-1-mediated CNS diseases is inflicted by HIV-1 infected brain macrophages.
Several steps of viral replication, including assembly and budding, differ between macrophages and T cells; it is likely that
cell-specific host factors mediate these differences. We previously defined Annexin 2 (Anx2) as an HIV Gag binding partner
in human monocyte-derived macrophages (MDMs) that promotes proper viral assembly. Anx2, a calcium-dependent
membrane-binding protein that can aggregate phospholipid-containing lipid rafts, is expressed to high levels in
macrophages, but not in T lymphocytes or the 293T cell line. Here, we use bimolecular fluorescence complementation in
the 293T cell model to demonstrate that Anx2 and HIV-1 Gag interact at the phosphatidylinositol (4,5) bisphosphate-
containing lipid raft membrane domains at which Gag mediates viral assembly. Furthermore, we demonstrate that Anx2
expression in 293T cells increases Gag processing and HIV-1 production. These data provide new evidence that Anx2, by
interacting with Gag at the membranes that support viral assembly, functions in the late stages of HIV-1 replication.
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Introduction
Direct infection of the brain by HIV-1 causes the AIDS-
definining illness HIV-associated dementia (HAD) as well as a
spectrum of motor and cognitive disorders [1,2]. Though neuronal
death and damage are a hallmark of the pathology associated with
HAD, neurons themselves are not infected. Instead, monocyte-
derived macrophages (MDMs) and parenchymal microglia are the
productively infected cells within the brain [2,3], and it is the viral
proteins and inflammatory mediators released by these cells that
damage neurons either directly or by causing glial dysfunction
(reviewed in [2,4]. Moreover, as HIV enters the brain within
weeks after initial infection and potentially years before neurolog-
ical symptoms develop [5,6], it is likely that brain macrophages
serve as long-lived viral reservoirs in the immunologically and
pharmacologically protected central nervous system (CNS) [7].
Given the critical role of macrophages in the neuropathogenesis of
AIDS, understanding aspects of HIV replication that may be
unique to these cells is a crucial step toward developing more
specific and effective antiretroviral therapies to treat HIV-
mediated CNS disease.
Several aspects of HIV replication differ in macrophages from
the more extensively studied CD4+ T cells, including the
coreceptor used for entry, the mechanisms regulating nuclear
import and viral transcription, and the cellular location of
assembly and budding (reviewed in [8]). As these cells serve vastly
different functions in the immune response, it is likely that many of
the differences in viral replication are due to differential protein
expression and regulation between the two cell types. We recently
undertook studies to identify macrophage-specific proteins that
function in HIV-1 assembly and budding [9].
HIV-1 assembly is mediated by the viral polyprotein p55
Gag, the
only viral protein necessary for the formation and release of virion-
like particles [10]. Gag is synthesized as a 55 kD precursor with
four domains that mediate the steps of virion assembly, budding,
and release [11]. During or immediately after assembly, the viral
protease cleaves p55
Gag into the matrix (MA, p17), capsid (CA,
p24), and nucleocapsid (NC, p7) proteins that form the structure of
the mature, infectious virion.
Recent evidence has shown that Gag preferentially mediates
viral assembly at specific membrane microdomains. These
domains are cholesterol-enriched lipid rafts that contain the
phospholipid phosphatidylinositol (4,5) bisphosphate
(PtdIns(4,5)P2) [12–24] and that are enriched in endosomal
tetraspannins and sorting machinery [25–27]. Host proteins that
regulate membrane phospholipids, cholesterol, and endosomal
components may thus play important roles in the late stages of
viral replication. We identified Anx2 as a HIV-1 Gag-interacting
protein in productively infected MDMs in an effort to discover
cellular proteins that influence viral assembly and budding in these
cells [9,28]. Anx2 is expressed highly in macrophages but not in T
cells [9], and the described functions of Anx2 make it a good
candidate as a possible regulator protein.
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binding protein with roles in both extracellular signaling and the
intracellular regulation of membrane composition and dynamics.
Extracellular and cell-surface associated Anx2 is involved in
plasmin generation [29] and cytokine production by macrophages
[30,31], and has been proposed to facilitate HIV-1 binding to and
entry into macrophages [32]. In the cytoplasm, Anx2 binds to
endosomal membranes [33] and is important in both early and
late phases of the endocytic pathway [34–37]. The mechanisms by
which Anx2 functions in these dynamic membrane events may
involve one of several abilities to influence membrane composition
and aggregation. Anx2 can mediate the lateral association and
stability of cholesterol-rich microdomains [38–40], concentration
of proteins destined for endocytic pathways [41–44] and induction
of the formation of stable PtdIns(4,5)P2 clusters within membranes
[45]. The ability of Anx2 to regulate endosomal trafficking as well
as cholesterol and PtdIns(4,5)P2 within cellular membranes make it
an attractive host protein important for HIV-1 assembly and
budding in macrophages.
Our previous experiments [9] suggested a role for Anx2 in viral
assembly based on the following evidence: first, Anx2 and Gag
were only co-immunoprecipitated in activated, productively
infected macrophages and not in quiescent macrophages in which
there was a block to HIV replication at a late step in the viral life
cycle [46]; second, both Gag and Anx2 colocated with CD63+ late
endosomal compartments in infected macrophages, the same
compartments in which mature virions accumulate [9,47–50]; and
third, downregulation of Anx2 resulted in decreased viral
replication, aberrant Gag processing, and failure of mature virions
to accumulate in intracellular vesicles. A subsequent study by
Chertova et al. demonstrated that Anx2 is incorporated into
virions released from HIV-1 infected MDMs [51], presenting
further evidence that it is present at the site of viral assembly.
As MDMs are difficult to transfect and display donor-to-donor
variability in protein expression, we chose here to use the 293T
cell line to further define the role of Anx2 in viral replication.
Multiple recent studies have taken advantage of the ease of
transfection of epithelial cell lines such as 293T and HeLa cells to
study the role of host components such as PtdIns(4,5)P2 [20,22],
cholesterol [16,17,19,24], and host proteins [52–58] in HIV-1
assembly and budding. Furthermore, as 293T cells do not express
endogenous Anx2, they allow us to control Anx2 expression levels
and give us a model in which to study the effects of Anx2 gain-of-
function on viral replication. Based on our previous observations
in MDMs, we hypothesized that Anx2 helps form a membrane
scaffold from which HIV-1 buds. Here, we investigate the location
and nature of the membranes at which Anx2 and Gag interact and
confirm these proteins bind at the PtdIns(4,5)P2–enriched lipid
rafts at which HIV assembles. Furthermore, in accordance with
our loss-of-function findings in MDMs, we report that Anx2 gain-
of-function enhances Gag processing and viral production. These
studies contribute to our understanding of HIV-1 replication in
macrophages, the major mediators of HIV-1 associated neurologic
disease.
Results
Anx2 was incorporated into virions produced by MDMs
and 293T cells
We previously reported that Anx2 and Gag co-precipitated
when co-transfected into 293T cells [9]. To examine whether
Anx2 and Gag interact at the site of viral assembly, we
cotransfected 293T cells with a molecular clone expressing Anx2
and the infectious clone HIV-1YU2, an M-tropic provirus cloned
from the brain of a patient with the AIDS dementia complex
[59,60]. Transient transfection of Anx2 into these cells resulted in
Anx2 expression levels comparable to that in both mock- and
HIV-infected macrophages with some experiment-to-experiment
variability much like the donor-to-donor variability seen with
primary macrophages (Fig. 1A). Untransfected 293T cells
expressed no detectable endogenous Anx2.
As an initial step in determining the site of interaction, we first
examined whether Anx2 was present in released virions. Chertova
et al. (2006) recently reported that Anx2 is incorporated into
virions produced by HIV-1 infected MDMs, evidence that in these
cells viral assembly occurs at membranes on which this protein is
concentrated [49,50]. To confirm this finding, supernatants from
HIV-1YU2-infected MDMs were filtered through 0.45 um filters to
remove cells, and viral particles were precipitated by ultracentri-
fugation before analysis by SDS-PAGE and western blot. As
shown in Fig 1B, the pellets from infected macrophages contained
Anx2 as well as mature capsid (p24
Gag), confirming that Anx2 was
indeed incorporated into virions. The cellular release of micro-
vesicles containing Anx2 was an unlikely alternative explanation,
as the pellets from uninfected MDMs contained no Anx2. The
absence of cellular debris in the pellets was confirmed by the
absence of GAPDH.
We next determined whether in 293T cells Anx2 was also
present at the site of viral assembly. Virions in the supernatants of
293T cells cotransfected with HIV-1YU2 and Anx2, HIV-1YU2 and
empty vector, or Anx2 alone were pelleted in the same way as the
MDM virions. Anx2 was present in virions from 293T cells
overexpressing the protein, but not in cells cotransfected with
HIV-1YU2 and empty vector (Fig. 1B). To determine whether the
extent of Gag processing influenced Anx2 incorporation, we also
analyzed virion-like particles released from cells treated with the
protease inhibitor indinavir sulfate (Ind) and in multiple repetitions
of the experiment we did not observe significant differences in the
extent of Anx2 incorporation. Anx2 was not present in pellets from
293T cells transfected with Anx2 alone, and GAPDH was absent
from all pellets, again indicating that cellular microvesicles or
secreted Anx2 were an unlikely source of the Anx2 in the pellets.
To confirm the direct association between HIV-1 virions and
Anx2, we immunoprecipitated virions using HIV-IG
TM (see
Materials and Methods) and analyzed precipitated virions for
the presence of Anx2 by SDS-PAGE and western blot. Virus
precipitated in the absence of detergent from the supernatants of
293T cells cotransfected with HIV-1YU2 and Anx2 contained
Anx2 (Fig. 1C); the presence of Anx2 was not due to non-specific
binding of HIV-IG to Anx2, as Anx2 was not brought down with
this procedure from supernatants of 293T cells transfected with
Anx2 alone. Interestingly, Anx2 was not pulled down when virions
were lysed in 0.5% Triton X-100 prior to immunoprecipitation
(Fig. 1C), suggesting that while Anx2 initially binds Gag and is
incorporated into virions during the process of viral assembly, the
Gag-Anx2 association is lost within the infectious virion, perhaps
due to the processing of full-length Gag. These data confirm that
Anx2 was incorporated into HIV-1 released from 293T cells, as it
is from HIV-1 released from macrophages, and thus provide
evidence that Anx2 was present at the site of viral assembly in
these cells.
Anx2 and Gag were both present in detergent-resistant
membrane fractions of 293T cells
Gag preferentially mediates HIV-1 assembly and budding from
detergent-resistant, cholesterol-rich lipid raft membrane domains
[15,19,24,47,61]. To determine whether Gag and Anx2 are both
present in these membrane domains in HIV-1YU2 and Anx2
HIV and Annexin 2
PLoS ONE | www.plosone.org 2 March 2009 | Volume 4 | Issue 3 | e5020Figure 1. Anx2 was present in virions released from 293T cells and localized with Gag to detergent resistant membrane domains.
(A) Western blot analysis of lysates from 293T cells transfected with HIV-1YU2+Vector or HIV-1YU2+Anx2 and MDMs either uninfected or infected with
HIV-1YU2. Anx2 expression in transfected 293T cells was comparable to that in MDMs. (B) (Left Panel) Human peripheral blood mononuclear cells
(PBMCs) were differentiated into monocyte-derived macrophages (MDMs) and infected for 48 hr with HIV-1YU2 (200 ng p24
Gag/six-well plate well).
The supernatants collected eleven days after infection were clarified, and aliquots of 1 mL were passed through 0.45 mM filters. Virus pellets were
obtained by ultracentrifugation of the filtered supernatants and analyzed by SDS-PAGE and western blot. Anx2 was present in the pellets obtained
from the supernatants of infected macrophages but not in those from uninfected macrophages. GAPDH was not detected, ensuring that the pellet
was not contaminated with free cellular material. (Right Panel) 293T cells were cotransfected with plasmids encoding HIV-1YU2 and Anx2, HIV-1YU2
and empty vector, or Anx2 alone. As indicated, some cells were treated with 50 mM indinavir sulfate (IND – an HIV protease inhibitor) immediately
after transfection. Thirty-six hours later, the supernatants were collected and virions were pelleted and analyzed in the same manner as those from
the MDMs. Anx2 was also present in the pellets from 293T cells cotransfected with HIV-1YU2 and Anx2 but not under the control conditions. Indinavir
sulfate had no effect on the apparent level of Anx2 in the virion pellet over several experiments. In the absence of protease inhibitor, the Gag signal
had mobility consistent with mature capsid, but it was a larger smeared band in the presence of the inhibitor. (C) Supernatants from 293T cells
transfected with Anx2 alone or with HIV-1YU2 and Anx2 were precleared with Protein G agarose beads before incubation with HIV-Ig to bind either
intact virions or virions lysed in 0.5% Triton-X-100. Western blot analysis of immunoprecipitated proteins demonstrates that Anx2 was present with
mature capsid (p24
Gag) in intact virions. Lysing the virions prevented the co-immunoprecipitation of capsid and Anx2, indicating the Anx2-Gag
interaction is lost in the mature virion. (D) 293T cells were cotransfected with plasmids encoding HIV-1YU2 and Anx2. Thirty-six hours later, cells were
subjected to membrane flotation ultracentrifugation in the presence of 1% Triton X-100 as described in materials and methods. Fractions were
combined, concentrated, and analyzed by SDS-PAGE and western blot against Gag, Anx2, the non-raft-associated membrane protein Transferrin
receptor (TFR), and the raft-associated membrane protein Flotillin-1 (Flot-1). Detergent resistant membranes floated to fractions 2–5 while cytosol
and detergent sensitive membrane remained in fractions 9–12. Anx2 and Gag were present in the lipid raft domains.
doi:10.1371/journal.pone.0005020.g001
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ultracentrifugation using a protocol previously employed to study
the extent of Gag-membrane binding [19,62–64]. Thirty-six hours
after transfection, cells were lysed in buffer containing 1% Triton
X-100, adjusted to 73% sucrose, overlayed with 65% and 10%
sucrose solutions, and spun at 100,0006g for 20 hrs at 4uC.
Twelve fractions were collected from the top of the gradient,
combined in pairs, and concentrated before analysis by SDS-
PAGE and western blot. As lipid rafts by definition are insoluble in
Triton-X-100 at 4uC [42], these microdomains and associated
proteins, such as Flotillin-1 (Flot-1), floated and were over-
represented in fractions 2–5, while proteins associated with the
cytoplasm or detergent-soluble membranes, such as Transferrin
Receptor (TFR), remained in fractions 9–12 (Fig. 1D). Both Gag
and Anx2 were present in fractions 3–4, indicating a proportion of
both proteins localized to detergent resistant lipid raft micro-
domains. The increased prevalence of p55 relative to capsid (p24)
in these domains is consistent with processed capsid being released
from membrane-bound matrix (p17) [11].
Bimolecular fluorescence complementation revealed that
Gag and Anx2 interacted at the plasma membrane of
293T cells
To determine whether Gag and Anx2 interacted at lipid rafts,
we attempted to co-immunoprecipitate Gag and Anx2 from the
detergent-resistant membrane fractions but were unsuccessful,
perhaps because of the relatively low protein concentrations. We
thus tested our hypothesis that Gag and Anx2 interacted at lipid
rafts using bimolecular fluorescence complementation (BiFC), a
technique used to study protein-protein interactions in which
individually inactive fragments of yellow fluorescent protein (YFP)
are fused to proteins of interest. Binding of the fusion proteins
when coexpressed in cells brings the YFP fragments in close
proximity, allows them to fold together, and results in the
formation of a fluorescing complex. Because BiFC does not
require cell lysis or antibody staining, it enables the visualization of
protein-protein interactions in living cells in their proper
intracellular environment [65]. Furthermore, only the fraction of
the expressed protein taking part in the interaction is visible,
making the determination of the intracellular site of binding more
precise. This technique has been used to study, in particular,
membrane-associated protein complexes for which the presence of
membrane is essential [65,66] and has recently been used to study
HIV Gag interactions and Gag trafficking [67,68].
We used the well-characterized interaction between Anx2 and
its cellular binding partner p11 [69] to develop the BiFC assay.
YFP-fragment fusion proteins were created with Anx2 fused to
fragment 1 of YFP at either the C-terminus (Anx2C-FR1) or N-
terminus (Anx2N-FR1) of the construct. Binding partner p11 was
also fused to fragment 2 of YFP (p11N-FR2) (Fig. 2A). Thirty-six
hours after transfection with the Anx2 and/or p11 BiFC
constructs, 293T cells were fixed, stained with DAPI, and
visualized by confocal microscopy. Expression of either Anx2C-
YFP1 or p11N-YFP2 alone did not produce YFP fluorescence
(Fig. 2B). Furthermore, cotransfection of constructs expressing
the two YFP fragments unlinked to a protein of interest (YFP-1
and YFP-2) also failed to produce fluorescence (Fig. 2B).
Cotransfection of Anx2C-YFP1 with p11N-YFP2, however,
resulted in fluorescence complementation, indicating a direct
interaction between Anx2 and p11 (Fig. 2C).
We then created two constructs with Gag fused to fragment 2 of
YFP, one encoding full-length Gag and another encoding the N-
terminal matrix-capsid region of Gag (p41
Gag) (Fig. 2A).
Cotransfection of p41
Gag and Anx2C resulted in fluorescence
complementation as demonstrated in Fig. 2D. There was no
difference in signal intensity or localization when Anx2N was used
instead of Anx2C, and Anx2C was therefore used for all further
experiments. While both Gag constructs produced fluorescence
complementation when cotransfected with Anx2, the signal
resulting from p41
Gag was greater than that from full-length Gag
(not shown). Complementation between p41
Gag and Anx2C
indicated that the Anx2 binding site on Gag is located in the
matrix and/or capsid regions, and the reduced fluorescence
observed with full-length Gag is likely due to the greater distance
between YFP fragments in the Anx2-Gag complex. The YFP
fluorescence was detected at the plasma membrane of p41
Gag and
Anx2C cotransfected cells (Fig. 2D), indicating that the Anx2-
p41
Gag interaction occurred at the plasma membrane, the site of
virion assembly and budding in 293T cells [70–73]. There was no
signal attributable to binding within intracellular organelles or
vacuoles.
To ensure that the fluorescence complementation between
Anx2C and p41
Gag represented a direct interaction between the
two proteins and not mere close proximity, we prepared a CD63-
YFP fragment 1 construct as a negative control (Fig. 2A). In 293T
cells, CD63 is expressed at the plasma membrane in addition to
intracellular compartments and is incorporated into released HIV-
1 virions [[74] and data not shown)] and is therefore present near
the site of viral assembly. Cotransfection of CD63 and p41
Gag
produced no fluorescence despite expression of both CD63 and
p41 in similar regions of the cell as indicated by immunolabeling of
the proteins and examination by confocal microscopy (Fig. 2E).
This result confirmed the specificity of the Anx2-p41
Gag
interaction.
Anx2 and Gag interacted at GM1-containing lipid rafts in
the plasma membrane of 293T cells
HIV-1 preferentially assembles at and buds from lipid raft
membrane microdomains [16–19]. To determine whether the
p41
Gag-Anx2 interaction occurred at these regions of the plasma
membrane, 293T cells transfected with the BiFC constructs were
incubated with Alexa FluorH 594-conjugated cholera toxin B
(CTB), which binds to the raft component ganglioside M1 (GM1)
[75,76]. The CTB-labeled rafts were then crosslinked with anti-
CTB antibody in order to create distinct raft patches on the
plasma membrane [77] and visualized by confocal microscopy.
YFP fluorescence colocated with the GM1-containing membrane
patches, indicating that the Anx2-p41
Gag interaction occurred on
GM1-containing lipid raft regions of the plasma membrane
(Fig. 3) and providing further support that Gag and Anx2 interact
at the site of virion assembly and budding.
The Anx2-Gag interaction was dependent on the
intracellular location and levels of PtdIns(4,5)P2
Along with lipid raft components, the phospholipid
PtdIns(4,5)P2, plays an important role in the targeting and binding
of Gag to the plasma membrane [21]. Whereas in normal HeLa
cells Gag is directed to the plasma membrane, redirection of
PtdIns(4,5)P2 from the plasma membrane to internal
PtdIns(4,5)P2-rich endosomal structures also redirects Gag and
viral budding to these structures [20]. Depletion of PtdIns(4,5)P2
altogether also causes failure of Gag trafficking to the plasma
membrane and instead accumulation of Gag in late endosomes
[20]. Both manipulations of PtdIns(4,5)P2 reduce viral production
[20].
To determine whether the Anx2-Gag interaction occurred on
PtdIns(4,5)P2-containing membrane domains, we altered the levels
HIV and Annexin 2
PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e5020Figure 2. Bimolecular fluorescence complementation (BiFC) showed that Anx2 and p41
Gag interacted at the plasma membrane of
293T cells. 293T cells transfected with the indicated constructs were stained with DAPI and visualized by confocal microscopy 36 hours post-
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effects of these manipulations on fluorescence complementation
between Anx2 and p41
Gag. The results described below were the
predominant effects observed in multiple fields of cells. To
visualize PtdIns(4,5)P2, we used a construct expressing GFP fused
to the pleckstrin homology (PH) domain of phospholipase C-d
(PHPLCd-GFP) that has been shown to bind to PtdIns(4,5)P2 [78].
When transfected alone into 293T cells, PHPLCd-GFP localized
primarily to the plasma membrane as previously demonstrated
(Fig. 4A) [20,78]. To redistribute PtdIns(4,5)P2 away from the
plasma membrane, we cotransfected 293T cells with PHPLCd-GFP
and HA-tagged ADP-ribosylation factor 6/Q67L (Arf6/Q67L), a
constitutively active form of Arf6 which causes intracellular
accumulation of PtdIns(4,5)P2-enriched endosomal structures
[79,80] to which Gag [20] and Anx2 [81] are directed.
Cotransfection of Arf6/Q67L with PHPLCd-GFP redistributed
GFP expression away from the plasma membrane and into
intracellular formations, indicating redirection of PtdIns(4,5)P2
(Fig. 4B). When co-transfected with myc-tagged phosphoinosi-
tide-specific inositol polyphosphate 5-phosphatase IV (5ptase IV),
an enzyme that depletes PtdIns(4,5)P2 [82], GFP became diffusely
distributed throughout the cell, indicating depletion of
PtdIns(4,5)P2 from the plasma membrane (Fig. 4C); this effect
has been previously observed in HeLa cells [20].
We next tested the effect of these manipulations of PtdIns(4,5)P2
on BiFC between Anx2 and p41
Gag in 293T cells. As described
above, transfection of Anx2 and p41
Gag resulted in YFP
fluorescence at the plasma membrane, indicating that the site of
viral assembly is the site of interaction between these two
proteins (Fig. 4D). Cotransfection of the BiFC constructs with
Arf6/Q67L redirected YFP from the plasma membrane to
intracellular compartments, indicating that the Anx2-Gag
complex was redirected to the PtdIns(4,5)P2-containing endoso-
mal structures (Fig. 4E). When Anx2 and p41
Gag were
cotransfected with 5ptase IV, YFP was no longer detected,
indicating that the absence of PtdIns(4,5)P2 inhibited the
interaction between the two proteins (Fig. 4F).T h i sf a i l u r eo f
fluorescence complementation is despite expression of p41
Gag
that was comparable to cells in which 5ptase IV is not expressed
as indicated by immunolabeling of Gag (Figs. 4D, F middle
panels). These data indicated not only that the Anx2-Gag
interaction occurred preferentially on PtdIns(4,5)P2-enriched
membranes, but also that the presence of PtdIns(4,5)P2 was
necessary for this interaction to occur efficiently.
Our experiments demonstrating that Gag and Anx2 interacted
at the PtdIns(4,5)P2 enriched lipid raft membrane domains at
which viral assembly occurs in 293T cells support a role for this
protein in HIV-1 assembly and budding. A functional role for
Anx2 was also suggested by our previous loss-of-function studies
showing that siRNA-mediated downregulation of Anx2 in
macrophages led to decreased viral replication, aberrant Gag
processing, and failure of mature virions to accumulate in
intracellular vesicles [9]. To identify a gain-of-function role for
Anx2, we compared Gag processing and viral production in 293T
cells co-transfected with HIV-1YU2 and Anx2 to those co-
transfected with HIV-1YU2 and empty vector.
transfection. (A) BiFC constructs. N and C in the designation denote location at the N- or C-terminus of the construct, respectively. Gly: Glycine linker
(not to scale). (B) No YFP fluorescence was detected in 293T cells transfected with single constructs or in cells cotransfected with both YFP fragments.
(C) YFP fluorescence, indicating an interaction between p11 and Anx2, was detected in 293T cells cotransfected with p11 and Anx2 BiFC constructs
(positive control). (D) YFP fluorescence, indicating an interaction between p41
Gag and Anx2, was detected at the plasma membrane of 293T cells
cotransfected with p41
Gag and Anx2 BiFC constructs. (E) No YFP fluorescence was detected in cells cotransfected with p41
Gag and CD63 BiFC
constructs (left panel), despite colocalized expression of CD63 and p41
Gag as demonstrated by immunolabeling (right panel). These data indicated
CD63 and p41
Gag did not interact and confirmed the specificity of the fluorescence complementation between p41
Gag and Anx2.
doi:10.1371/journal.pone.0005020.g002
Figure 3. Anx2 and Gag interacted at GM-1-containing lipid rafts in the plasma membrane of 293T cells. 293T cells cotransfected with
p41
Gag and Anx2 BiFC constructs were fixed and incubated with Alexa FluorH 594 conjugated cholera toxin B (CTB) to label the lipid raft component
ganglioside M1 (GM1) followed by crosslinking of the raft regions with anti-CTB antibody. YFP colocalized with CTB-containing patching, indicating
that p41
Gag and Anx2 interacted at GM1-containing lipid rafts.
doi:10.1371/journal.pone.0005020.g003
HIV and Annexin 2
PLoS ONE | www.plosone.org 6 March 2009 | Volume 4 | Issue 3 | e5020Figure 4. The Anx2-p41
Gag interaction occurred at PtdIns(4,5)P2-enriched membrane domains and depended on intracellular levels
of PtdIns(4,5)P2. 293T cells transfected with the indicated constructs were immunostained for protein (p41) or tag (HA, c-myc), labeled with DAPI
and visualized by confocal microscopy 36 hours post-transfection. (A) PHPLCd-GFP labeled PtdIns(4,5)P2 at the plasma membrane of 293T cells. (B)
Arf6/Q67L redirected PtdIns(4,5)P2 and thus PHPLCd-GFP to intracellular membranes. Cells expressing Arf6/Q67L were identified by immunolabeling
HIV and Annexin 2
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1 production in 293T cells
We noted that in many co-transfection experiments Anx2
expression appeared to enhance the processing of Gag into mature
capsid (p24
Gag), an event associated with maturation of assembled
virions. To quantify this effect, we analyzed cell lysates from three
independent transfections in which this enhancement was seen.
Lysates were subjected to SDS-PAGE followed by western blotting
with HIV Immunoglobulin and antibody to b-actin (Fig. 5A).
When normalized to b-actin levels, Anx2 increased total Gag
levels in each transfection, but when averaged over all 3
experiments the increase was not statistically significant
(p=0.096) However, Anx2 did increase the percent of total Gag
that was processed into mature capsid (p24) from an average of
26.8% to 43.6%, an effect that was highly statistically significant
(p,0.002) (Fig. 5B). Measurement of intracellular p24
Gag
concentration in these lysates by ELISA confirmed that Anx2
increased intracellular capsid levels (Fig. 5C). The increase in
Gag processing was not observed in every transfection, so to better
quantify the overall effects of Anx2 on intracellular capsid levels,
lysates from 19 independent co-transfections of 293T cells with
HIV-1YU2 and Anx2 were analyzed for p24
Gag concentration
using ELISA. Anx2 increased the intracellular p24
Gag concentra-
Figure 5. Anx2 gain-of-function in 293T cells increased Gag processing and viral production. (A) 293T cells were cotransfected with HIV-
1YU2 and either empty vector or Anx2. At 36–48 hrs after transfection, the cells were lysed in 0.5% Triton-X. Lysates from 3 independent transfections
were analyzed by SDS-PAGE and western blot with HIV-Ig, anti-Anx2, and anti-b-actin. Anx2 increased processing of p55
Gag into mature capsid
(p24
Gag). (B) Quantification of the western blot in (A) with NIH Image J. Anx2 increased the percent of total Gag processed into mature capsid
(p24
Gag)( p ,0.002) using a correlated samples two-tailed student’s t-test. Error bars represent standard deviations. (C) The p24
Gag concentration of
the lysates shown in (A) was determined by ELISA. Anx2 increased the mature capsid concentration as suggested by the western blot analysis in (A).
(D) Lysates from 19 different transfections of HIV-1YU2 with either empty vector or Anx2 were prepared as in (A). p24
Gag concentrations of the lysates
were determined by ELISA. The average ratio of the experimental values (HIV-1YU2+Anx 2) to the control value (HIV-1YU2+vector) are shown on the bar
graph. The error bars represent standard errors of the means. Statistical analysis was performed using paired two-tail student’s t test. Anx2 increased
the intracellular concentration of mature capsid.
doi:10.1371/journal.pone.0005020.g005
for the HA tag (middle panel). (C) 5ptase IV depletes PtdIns(4,5)P2 and causes PHPLCd-GFP to be diffusely distributed throughout the cytoplasm and
nucleus. Cells expressing 5ptase IV were identified by immunolabeling for the c-myc tag (middle panel). (D) In 293T cells with normal PtdIns(4,5)P2
expression, the Anx2-p41
Gag interaction, as denoted by YFP fluorescence complementation, occurred at the plasma membrane where PtdIns(4,5)P2 is
located. (E) The Anx2-p41
Gag interaction was redirected to PtdIns(4,5)P2 –enriched intracellular membranes when 293T cells expressed Arf6/Q67L. (F)
Depletion of with 5ptase IV inhibited the Anx2-p41
Gag interaction as indicated by reduced YFP fluorescence complementation. Reduced binding
between Anx2 and p41
Gag is not due to reduced p41
Gag expression, as determined by immunolabeling of p41
Gag (middle panel).
doi:10.1371/journal.pone.0005020.g004
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was 90.2% (Fig. 5D).
In previous experiments, depletion of Anx2 in HIV-1 infected
macrophages not only impaired Gag processing but also reduced
virus production [9]. To determine whether Anx2 expression in
293T cells could have the opposite effect (i.e. increased viral
production), we measured p24
Gag concentration in the superna-
tants of the cells from 47 separate co-transfections of HIV-1YU2
with either Anx2 or empty vector at 36 hr post-transfection. Anx2
overexpression was associated with increased p24
Gag release into
the supernatant by an average of 68.8% (Fig. 6A). As with Gag
processing, however, there was experimental variability in the
effects of Anx2 on viral production, likely due to differences in
transfection efficiency and cell density between transfections. To
ensure that the Anx2-mediated increase in mature capsid
represented an increase in the production of infectious virus,
supernatants from three independent transfections demonstrating
this increase were used to infect TZM-bl cells, which express the
luciferase gene under control of the HIV-1 promoter and which
have been used previously to quantify virus infectivity [83–85].
The p24
Gag concentrations in cell supernatants from these three
transfections are shown in Fig. 6B; Anx2 significantly increased
the concentration of mature capsid in each transfection. To
quantify infectious virus, equal volumes of these supernatants were
applied to TZM-bl cells for 24 hours. The amount of infected cells
in each condition was then quantified by analyzing luciferase
expression (Fig. 6C). Consistent with the measured mature capsid
concentrations, supernatants from cells expressing Anx2 contained
significantly more infectious HIV-1 than control cells in each of
the three transfections. These data indicated Anx2 gain-of-
function in 293T cells led to enhanced Gag processing and
increased infectious viral production and thus support a functional
role for Anx2 in HIV-1 assembly and budding.
Discussion
Here we present further evidence that Anx2 plays a role in
HIV-1 assembly and budding by characterizing the intracellular
site of the Anx2-Gag interaction and by investigating the effects of
Anx2 gain-of-function on viral replication in 293T cells.
Bimolecular fluorescence complementation demonstrated that
Anx2 and Gag interacted at GM1-containing lipid rafts in the
plasma membrane, the membrane microdomains at which HIV
assembles in these cells [15,18,19,70–73]. Efficient formation of
the Anx2-Gag complex depended on the presence of
PtdIns(4,5)P2, a membrane phospholipid that targets Gag to the
plasma membrane and facilitates Gag-membrane binding [21–
23,86]. Redirection of PtdIns(4,5)P2 to intracellular membranes –
a manipulation that also redirects viral assembly [86] – also
redirected the complex to the cytoplasm. The presence of Anx2 at
the HIV-1 assembly site was confirmed in the context of whole
virus replication in 293T cells, as Anx2 was present with Gag in
detergent-resistant membrane fractions containing lipid rafts and
in the released virions. Finally, Anx2 gain-of-function in 293T cells
led to enhanced Gag processing and increased viral production,
findings that complement our previous studies showing that
knockdown of Anx2 in MDMs led to impaired Gag processing and
decreased viral production [9].
Based on the known functions of Anx2, we propose that the
most likely mechanism behind our results is Anx2-mediated
creation and/or stabilization of the PtdIns(4,5)P2-containing lipid
raft membrane domains from which the virus preferentially buds
Figure 6. Anx2 gain-of-function in 293T cells increased the production of infectious HIV-1. (A) 293T cells were cotransfected with HIV-
1YU2 and either empty vector or Anx2. At 36–48 hrs after transfection, the supernatants were collected and the p24
Gag concentrations were
determined by ELISA. The average ratios of the experimental values (HIV-1YU2+Anx 2) to the control values (HIV-1YU2+vector) are shown on the bar
graph. Data represent 46 different transfections; error bars represent standard errors of the means. Statistical analysis was performed using paired
two-tail student’s t test. Anx2 increased HIV-1YU2 production by 293T cells. (B) p24
Gag concentrations in the supernatants from three independent
transfections of 293T cells with either HIV-1YU2+Vector or HIV-1YU2+Anx2 were measured by ELISA. Anx2 increased viral production in each
transfection. Error bars represent standard deviations. Statistical analysis was performed using unpaired two-tail student’s t test. (C) Quantification of
infectious virus in the supernatants shown in (B) using TZM-bl cells expressing the luciferase gene under the control of the HIV-1 promoter. TZM-bl
were infected with equal volumes of supernatants from both control and Anx2-expressing 293T cells and luciferase expression in relative light units
(RLU) was determined after 24 hours and taken as a measure of the amount of infectious virus present. More infectious virus was present in the
supernatants of Anx2-expressing 293T cells in comparison with control cells in each of the three transfections. Error bars represent standard
deviations. Statistical analysis was performed using unpaired two-tail student’s t test.
doi:10.1371/journal.pone.0005020.g006
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recruit Gag to these domains. PtdIns(4,5)P2 interacts directly with
hydrophobic residues in the matrix domain of Gag and triggers
exposure of the N-terminal myristic acid [21], an event that is
important for membrane-binding [62,64,87,88]. A recent in vitro
study confirmed that efficient binding of Gag to liposomes requires
the presence of PtdIns(4,5)P2 [22]. After initial membrane binding,
Gag becomes associated with the highly ordered membrane
microdomains rich in sphingolipids and cholesterol known as lipid
rafts [19]. This localization may be facilitated by the Gag-
PtdIns(4,5)P2 interaction, as the unsaturated 29 side chain of the
phospholipids leaves the lipid bilayer to bind matrix, leaving the
saturated 19 fatty acid side chain [21,23]. Other studies have
suggested that lipid rafts may serve as platforms that enable the
higher order Gag multimerization that occurs after initial
membrane binding [19,24,63,89,90].
Anx2 can laterally aggregate and stabilize cholesterol-rich
microdomains [39,40]. Furthermore, Anx2 binds directly to
PtdIns(4,5)P2 [81,91] and can induce the formation of stable
PtdIns(4,5)P2 clusters within membranes in a cholesterol-depen-
dent manner [45]. At intracellular membranes in macrophages
and at the plasma membrane of 293T cells, Anx2 may thus help to
create and/or stabilize domains that enhance initial Gag-
membrane binding and facilitate Gag-Gag multimerization and
increase viral production. This mechanism would explain
increased Gag processing, as enhanced lipid raft-binding and
Gag multimerization would in turn facilitate dimerization of Gag-
Pol precursors within the assembling virion [92] and thus
activation of the viral protease. As noted, siRNA-mediated
depletion of Anx2 in HIV-1 infected macrophages not only
reduced overall virion production but also induced defects in Gag
processing that were associated with reduced infectivity of released
virions, effects that we hypothesized resulted from destabilization
of lipid rafts in the absence of Anx2 [9].
The localization of Anx2-Gag complexes to GM1 and
PtdIns(4,5)P2-containing membrane domains, as well as the
dependence of the interaction on the levels and location of
PtdIns(4,5)P2, are consistent with the scenario in which Anx2-
mediated stabilization of such domains is important for Anx2-Gag
binding and HIV-1 assembly. Of note, in HIV-1 infected MDMs
Anx2 and Gag collocated with CD63 positive internal membranes,
in contrast to the plasma membrane localization of the Anx2-Gag
BiFC complexes in 293T cells. Importantly, the membranes at
which the interaction occurs represent the site of viral assembly in
each cell type [48–50,70–73,93]. In both MDMs [9] and transfected
293Ts (not shown), Anx2 expression was diffusely distributed and
not confined to areas of collocation with Gag. Our data do not
distinguish between the two most likely explanations for the different
sites of the Gag-Anx2 interaction: first, that the ability of Anx2 to
perform its function in viral assembly is spatially regulated by cell-
specific factors in endosomal membranes in MDMs and in the
plasmamembrane in293Tcells,leadingtoGag recruitment to those
sites; or second, that Anx2 performs its function throughout each cell
but Gag targeting is mediated by another cell-specific molecule or
mechanism. Cell-specific distribution of PtdIns(4,5)P2 may be one
such mechanism, as its redistribution from the plasma membrane
redirected both viral assembly [20] and the Anx2-Gag interaction to
PtdIns(4,5)P2-enriched internal membranes. We are currently
performing studies to determine the relationship between
PtdIns(4,5)P2 localization and Anx2 function in MDMs.
There are several other potential, though not mutually
exclusive, explanations for the increase in viral production seen
with Anx2. For example, binding between Anx2 and Gag could
induce conformational changes in Gag, possibly triggering the
myristyl switch that enhances Gag-membrane binding. Anx2 can
also promote the aggregation and fusion of membrane-bound
structures such as secretory granules with the plasma membrane
and endosomes with each other [94–99]. The latter function is
thought to be relevant in CMV infection, as Anx2 can enhance the
fusion of CMV with phospholipid-containing membranes
[100,101]. Anx2 might similarly facilitate this process for HIV,
which also requires fusion events for budding. Anx2 is an actin-
binding protein [102,103] with the ability to regulate actin
polymerization [104] and may act as a membrane-cytoskeletal
scaffolding protein [105]. Anx2 could thus facilitate HIV
production by mediating Gag-actin interactions and Gag traffick-
ing. Finally, as Anx2 is a multifunctional protein, overexpression
could have a general effect on cellular processes and only indirectly
increase viral assembly. Cotransfection of Anx2, however, did not
produce evident structural abnormalities by EM (data not shown)
or change the expression of cellular proteins such as GAPDH or B-
actin (Figs. 1A, 5A), arguing for a relatively specific effect of
Anx2.
Future experiments will more precisely determine the mecha-
nism by which Anx2 facilitates Gag-mediated assembly, budding,
processing and release. Ultimately, we hope to gain sufficient
understanding of this mechanism to determine the function of
Anx2 in HIV-1 replication in macrophages. As the host proteins
that regulate HIV replication are likely to be different in T cells
and macrophages [106], such an understanding will be crucial in
the eventual development of therapies to counteract the roles of
HIV-1 infected macrophages in viral transmission, reservoir
formation, and neuropathogenesis.
Materials and Methods
Plasmids and cell transfection
We received several plasmids as gifts from other laboratories:
the HIV-1YU2 proviral genome (RF-1) from Dr. M. Malim, King’s
College, London; PHPLCd-GFP from Dr. T. Balla, National
Institutes of Health [78]; 5ptase IV from Dr. P.W. Majerus,
Washington University School of Medicine, St. Louis, MO [82];
and Arf6/Q67L form Dr. J.G. Donaldson, National Institutes of
Health. Anx2 was cloned into the pcDNA3.1(+) vector (Invitrogen)
under control of the human CMV promoter. For BiFC, the coding
sequence for the N-terminal 160 residue fragment of YFP (FR1)
along with a linker segment of 12 glycines was cloned into the
pcDNA3.1(2) vector attached to either the N- or C-terminus of
Anx2. To construct p41
Gag-FR2, the matrix and capsid domains
of p55
Gag were amplified from the codon-optimized pGagEGFP
plasmid, a gift from Dr. M. Resh, Memorial Sloan-Kettering
Cancer Center. Four constitutive transport elements (CTE; a gift
from Dr. M. Malim, King’s College, London; [107]) were cloned
into the 39UTR of p41Opt. The p41
Gag segment and the C-
terminal 82 residues of YFP (FR2) along with a linker segment of
12 glycines were cloned into the pcDNA3.1(2) vector.
293T cells were transfected using the calcium-phosphate
method (Promega ProFection kit). For studies of the effect of
Anx2 on HIV replication, 1 ug YU-2 plasmid was co-transfected
with 3 ug of Anx2 or pcDNA 3.1. For BiFC, Anx2-FR1 and
p41
Gag-FR2 were co-transfected in the ratio of 1 ug Anx2 or
CD63: 2 ug p41
Gag or Gag along with 1 ug empty vector, 5ptase
IV, or Arf6/Q67L.
Bimolecular fluorescence complementation (BiFC) and
Immunofluorescence
Thirty-six hours after transfection, 293T cells were fixed in 4%
paraformaldehyde in PBS and permeabilized with 0.1% Triton-X.
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Applied Science, Germany), 5ptase IV with rabbit anti-c-Myc (A-
14) antibody (Santa Cruz), and Arf6/Q67L with rabbit anti-HA-
probe (Y-11; Santa Cruz). Cells were then incubated with Alexa
FluorH 488 chicken anti-mouse or anti-rabbit IgG (Invitrogen),
stained with DAPI (49,69-diamidino-2-phenylindole; Invitrogen)
and coverslipped with ProLongH Gold antifade reagent (Invitro-
gen). For collocation with GM1, cells were stained with
recombinant cholera toxin B (CTB) conjugated to Alexa FluorH
594 after fixation and CTB was then aggregated using anti-CTB
antibody (VybrantH Lipid Raft Labeling kit, Invitrogen). Fluores-
cence in the cells was analyzed using a Zeiss LSM 510 confocal
microscope. Images were taken with a LSM 510 camera and
processed with Adobe Photoshop CS.
Membrane flotation
Membrane flotation was performed as described previously
[62–64]. Thirty-six hours post-transfection, 293T cells were lysed
in Tris-EDTA (TE) buffer (10 mM Tris-HCl pH 7.5 with 1 mM
EDTA) containing 1% Triton X-100, 6% sucrose, and protease
inhibitors. Post-nuclear supernatants (PNS) were obtained by low-
speed centrifugation and 250 mL were adjusted to 73.3% sucrose
with 1.25 mL 85.5% sucrose in TE. The lysates were overlaid with
7 mL 65% sucrose in TE and 3.25 mL 10% sucrose in TE before
ultracentrifugation at 100,0006g for 18–24 hrs at 4uC. Twelve
1 mL fractions were collected from the top, and 150 mL fractions
were combined in pairs and proteins concentrated using the Pierce
SDS-PAGE Sample Prep Kit according to the manufacturer’s
protocol. Fractions were analyzed by SDS-PAGE and western blot
with rabbit polyclonal antiserum against HIV-1SF2 p24
Gag (AIDS
Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH), mouse anti-Anx2 (BD Biosciences, New Jersey),
mouse anti-Human Transferrin Receptor (Zymed, Invitrogen,
Carlsbad, CA), and mouse anti-Flotillin-1 (BD Biosciences).
Virus precipitation and analysis
Peripheral blood mononuclear cells derived from whole blood
by the University of Pennsylvania Center CFAR Immunology core
were plated (3.2 million cells/well) in six-well plates and
differentiated into macrophages for seven days. 293T cell
supernatants containing HIV-1YU2 (200 ng p24
Gag per well as
measured by p24
Gag ELISA) were applied to the monocyte-
derived macrophages (MDMs) for 48 hours, and infected MDM
supernatants were collected 11 days after infection. Cellular
material was pelleted by centrifuging the supernatants for 1 min at
16,1006g and then 1 mL of each clarified supernatant was passed
through 0.45 mm filters to further remove any cellular compo-
nents. Virus pellets were obtained by ultracentrifugation of the
filtered supernatants and then analyzed by SDS-PAGE and
western blotting with rabbit polyclonal antiserum against HIV-
1SF2 p24
Gag (AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH), mouse monoclonal anti-Anx2
antibody (BD Biosciences, New Jersey), and rabbit polyclonal anti-
GAPDH antibody (Abcam, Cambridge, MA). Virus pellets from
transfected 293T cells were prepared and analyzed in the same
manner.
Virus immunoprecipitation from cell supernatants
Supernatants from 293T cells transfected with Anx2 alone or
HIV-1YU2+Anx2 were collected 36 hours post-transfection. Before
immunoprecipitation, the cellular debris was pelleted by centrifu-
gation for 1 min at 160006g. 900 mL of each supernatant was
then added to 100 mL of PBS only or to 100 uL 5% Triton-X in
PBS to lyse the virions. The supernatants were pre-cleared with
50 mL recombinant protein G agarose (Invitrogen, Carlsbad, CA)
at 4uC for one hour before incubation with 5 mL HIV
Immunoglobulin (HIV-IG
TM from AIDS Research and Reference
Reagent Program, Division of AIDS, NIAID, NIH) overnight at
4uC. Fifty mL of fresh protein G beads were then added to the
supernatant-antibody mixture and incubated for 2 hr at 4uC. The
beads were washed twice in 0.5% Triton-X in PBS, once in PBS,
resuspended in 50 mL2 6SDS buffer and boiled for 5 min. Equal
volumes of immunoprecipitates were subjected to SDS-PAGE on
8–16% Tris-Glycine polyacrylamide gels (Lonza, Switzerland) and
western blotting with mouse monoclonal antibody against HIV-1
p24
Gag (#24-2, AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID, NIH) and mouse monoclonal anti-
Anx2 antibody (BD Biosciences, New Jersey).
Western blotting for Anx2 expression and Gag
Processing
293T cells at 36 hours post-transfection and MDMs at 10–14
days after infection with HIV-1YU2 were lysed in 0.5% Triton-X in
PBS with protease inhibitors (Complete, Roche Applied Science,
Germany) and protein concentrations were determined using the
Bio-Rad DC Protein Assay kit. Equal micrograms of each sample
were analyzed by SDS-PAGE and western blot. Antibodies used
for protein detection were HIV Immunoglobulin (HIV-IG
TM from
AIDS Research and Reference Reagent Program, Division of
AIDS, NIAID, NIH), mouse anti-Anx2 (BD Biosciences, New
Jersey), mouse monoclonal against beta actin (Abcam, Cambridge,
MA), and rabbit polyclonal against GAPDH (Abcam, Cambridge,
MA). NIH Image J was used to quantify bands. Statistical analysis
was performed using a two-tailed paired student’s t test.
p24
Gag protein measurement
36 hours post-transfection of 293T cells, supernatants were
collected and the cells were lysed in 0.5% Triton-X in PBS
supplemented with protease inhibitors (Complete; Roche Applied
Science, Germany). The Gag concentration in the supernatants
and cell lysates was measured in our laboratory using the p24
Gag
enzyme-linked immunosorbent assay (ELISA) as per the manu-
facturer’s instructions (Perkin-Elmer; NEK050) or by the Univer-
sity of Pennsylvania Center for AIDS Research (CFAR) Virus and
Molecular Core. The effect of Anx2 overexpression on Gag
concentration was calculated as the ratio of the experimental
values (HIV-1YU2+Anx2) over the control values (HIV-1YU2+-
vector) with control values set to one. Statistical analysis was
performed on the ratios using a paired two-tailed student’s t-test.
Error bars represent standard errors of the mean.
Quantification of infectious virus in 293T supernatants
TZM-bl cells are CD4- and CCR5-expressing HeLa cells that
contain the luciferase and b-galactosidase genes under the control
of the HIV-1 promoter (obtained from the NIH AIDS Research
and Reference Reagent Program, Division of AIDS, NIAID, NIH:
from Dr. John C. Kappes, Dr. Xiaoyun Wu, and Tranzyme Inc.)
TZM-bl cells in 96-well plates were incubated with 5 uL of virus-
containing supernatant from HIV-1YU2+Vector and HIV-
1YU2+Anx2 transfected 293T cells. Supernatants from three
independent transfections were used. After 24 hours of incubation,
the media was removed and the cells were lysed by exposure to
25 uL 16 Reporter Lysis Buffer (Promega, Madison, Wisconsin)
followed by one freeze-thaw cycle. One-hundred microliters of
Luciferase Assay Substrate (Promega) was added to each well and
the relative light units (RLU) were measured using a Packard
LumiCount luminometer and Packard PlateReader 3.0 software.
HIV and Annexin 2
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